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Cyclosporine A (CsA) is an immunosuppressive drug that targets cyclophilins, cellular cofactors that reg-
ulate the immune system. Replication of hepatitis C virus (HCV) is suppressed by CsA, but the molecular
basis of this suppression is still not fully understood. To investigate this suppression, we cultured HCV
replicon cells (Con1, HCV genotype 1b, FLR-N cell) in the presence of CsA and obtained nine CsA-resistant
FLR-N cell lines. We determined full-length HCV sequences for all nine clones, and chose two (clones #6
and #7) of the nine clones that have high replication activity in the presence of CsA for further analysis.
Both clones showed two consensus mutations, one in NS3 (T1280V) and the other in NS5A (D2292E).
Characterization of various mutants indicated that the D2292E mutation conferred resistance to high
concentrations of CsA (up to 2 lM). In addition, the missense mutation T1280V contributed to the recov-
ery of colony formation activity. The effects of these mutations are also evident in two established HCV
replicon cell lines—HCV-RMT ([1], genotype 1a) and JFH1 (genotype 2a). Moreover, three other missense
mutations in NS5A—D2303H, S2362G, and E2414K—enhanced the resistance to CsA conferred by
D2292E; these double or all quadruple mutants could resist approximately 8- to 25-fold higher concen-
trations of CsA than could wild-type Con1. These four mutations, either as single or combinations, also
made Con1 strain resistant to two other cyclophilin inhibitors, N-methyl-4-isoleucine-cyclosporin
(NIM811) or Debio-025. Interestingly, the changes in IC50 values that resulted from each of these muta-
tions were the lowest in the Debio-025-treated cells, indicating its highest resistant activity against the
adaptive mutation.
 2014 The Authors. Published by Elsevier Inc. This is an open access article under the CC BY-NC-ND
license (http://creativecommons.org/licenses/by-nc-nd/3.0/).1. Introduction (genotypes 1–6); genotype 1 is the most prevalent over most ofThe genome of the hepatitis C virus (HCV) is a single-stranded
RNA with positive polarity and is classiﬁed in the Flaviviridae fam-
ily. HCV frequently establishes chronic infections that lead to liver
cirrhosis and hepatocellular carcinoma (HCC) [2]. An estimated
130–200 million people worldwide are now infected with HCV
[3]. HCVs have been classiﬁed into six major genotypic groupsthe world. Treatments with alpha interferon (IFNa), together with
the nucleoside analog ribavirin (RBV), greatly increased the per-
centage of HCV chronically infected patients able to reach a sus-
tained anti-viral response (SVR). Covalent attachment of
polyethylene glycol (PEGylated) IFN-a-plus-RBV therapy has a suc-
cess rate of 80% in patients with genotype 2 or 3 infections, but
only 50% in patients with genotype 1 infections [4,5]. The
recently approved protease inhibitors boceprevir and telaprevir
each improved the efﬁcacy of IFN-a-plus-RBV therapy [6]. These
direct-acting agents (boceprevir, simeprevir, sofosbuvir, faldapre-
vir and telaprevir, etc.) each have the advantage of being highly
speciﬁc, but each may select for speciﬁc resistant mutations, limit-
ing their long-time efﬁcacy. Therefore, antiviral inhibitors target-
ing host factors crucial for viral replication should be developed
to overcome these problems.
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(Cyp) and modulate HCV replication [7–9]. To date, three Cyp
inhibitors—Debio-025, NIM811, and SCY-635—have been deemed
safe and effective for patients with HCV in phase I and II studies
[10–12]. Development of Debio-025 has advanced the farthest
through phase II studies, and Debio-025 has approved and showed
a great deal of promise for decreasing HCV viremia in infected
patients. However, emergence of drug-resistant HCV mutants
could limit the therapeutic potential of CsA and Cyp inhibitors.
The HCV genome is a positive-sense, single-stranded RNA
(about 9.6 kb) that encodes at least 10 viral proteins; these are
categorized as structural core proteins (E1, E2) or nonstructural
(p7, NS2, NS3, NS4A, NS4B, NS5A, and NS5B) [13,14]. The nonstruc-
tural proteins are involved in HCV RNA replication [14]. NS5A pro-
tein comprises three domains linked by two low-complexity
sequences (LCS) that are either serine or proline rich; domain I is
a highly structured zinc binding domain whose three-dimensional
structure shows two dimeric conformations [15,16]. Domains II
and III have been shown to be unstructured in their native states,
but nuclear magnetic resonance and circular dichroism have
shown that elements of secondary structure run throughout each
of these domains [17–19]. NS5A is anchored to membranes by an
N-terminal amphipathic helix and is an essential component of
the viral genome replication complex; it also interacts with other
non-structural proteins [20] or cellular factors. NS5A domain II is
a substrate for the peptidyl-prolyl cis/trans isomerase activity of
Cys A and B [21], and NS5A domain III is reportedly a substrate
of CypA [22].
In this study, we used CsA to select for and isolate drug-
resistant HCV mutants; we then performed virus genome
sequencing to investigate the molecular mechanisms of this drug
resistance.2. Materials and methods
2.1. Cells, electroporation and ethics statement
HuH-7 cells were cultured in DMEM-GlutaMax-I (Invitrogen,
Carlsbad, CA, USA) supplemented with 10% fetal bovine serum,
penicillin, and streptomycin (Invitrogen). Replicon cells were
maintained in the same medium supplemented with 300 lg/ml
G418 (Invitrogen). Cells were passaged three times a week, and
at each passage, each culture was split into four subcultures.
Electroporation of replicon RNA and G418 selection were per-
formed as previously described [23]. All experimental protocol
was approved by the regional research institute.
2.2. Establishment of cyclosporin A resistant replicon clones
FLR3-1 cells derived from Con1 (AJ238799)-based, luciferase-
harboring HCV sub-genomic replicon cell were treated with both
2 lM of cyclosporin A and 0.5 mg/ml of G418 for 24 days.
Surviving cells were further treated with 3 lM CsA for 2 days,
4 lM for 4 another days, and ﬁnally 6 lM for the last 10 days.
Using limiting dilution cloning, we established nine clonal cell
lines. Using real-time RT-PCR (ABI 7700 system, Applied
Biosystems, Foster City, CA, USA) as described previously [24], we
systematically measured HCV RNA copy number in each of these
nine clonal lines.
2.3. Determination of consensus sequence of resistant clones
LongRange Reverse transcriptase (QIAGEN, Valencia, CA, USA)
and an oligonucleotide primer (antisense sequence 9549–9569 of
HCV-Con1) were used to reverse transcribe puriﬁed RNA (1 lg).The resulting cDNA, Phusion DNA polymerase (Finnzymes, Vantaa,
Finland), and primers recognizing each non-coding region were
used for PCR ampliﬁcation of the entire non structural protein
coding region of the sub-genomic replicon. The TA cloning kit
(Invitrogen) was used to introduce each fragment into a separate
plasmid; we picked up eight clones from each resistant cell line
and their nucleotide sequences were determined.
2.4. Construction and RNA transcription
The pFK I389neo/NS3-30/5.1 and pFK I389luc/NS3-30/5.1
plasmids (ReBlikon, Baden-Württemberg, Germany) were used to
generate HCV constructs with regions of the sub-genomic replicon
with mutations (Fig. 2A). The QuikChangeII kit (Stratagene, La Jolla,
CA, USA) was used to introduce speciﬁc mutations into the HCV
sequences. To generate RNA, plasmids were digested with XbaI
and used as a template for RNA transcription; RiboMax (Promega,
Madison, WI, USA) was used for each transcription reaction.
2.5. Drug treatment
For the drug resistance assays, established CsA-resistant repli-
con clones were seeded onto 24-well tissue culture plates
(10,000 cells/well) and cultivated overnight. Then cells were
treated with various concentrations of CsA (0–8 lM) for 4 days.
Surviving cells were stained with crystal violet.
For HCV replication inhibition assays, replicon cells were
seeded in 96-well tissue culture plates (5000 cells/well) and
cultivated overnight. Serial dilutions of CsA (Fluka Chemie, Buchs,
Switzerland) or NIM811 (Novartis) and Debio025 (Debiopharma)
were then added to sets of wells. After incubation for 72 h, ABI
prizm 6100 (Applied Biosystems) was used to extract total RNA
from cells, and HCV-RNA was measured as described above. Each
assay was carried out in triplicate.
For another HCV replication inhibition assay, mutant replicon
RNA derived from pFK I389luc/NS3-30/5.1 plasmid were introduced
into HuH7 cells via electroporation, and the transformed/
transfected cells were seeded to 96-well tissue culture plates.
Drugs were added 24 h after electroporation. Luciferase activities
were evaluated 4 h or 72 h after electroporation, which corre-
sponded to 20 h before drug treatment or 48 h after drug treat-
ment, respectively; the Blight-Glo kit (Invitrogen) and Envision
(Perkin Elmer, Waltham, MA, USA) were used to take all measure-
ments, and values at 72 h were normalized relative to the values
from 4 h.3. Results
3.1. Establishment of CsA-resistant clones
To establish CsA-resistant clones, we treated HCV FLR-N repli-
con cells with CsA (Fig. 1A) and obtained nine resistant clonal cell
lines. We measured the amount of HCV RNA in each resistant clo-
nal line and chose for further study the three lines that consistently
had the largest amount of HCV RNA (Fig. 1B). We then determined
the entire HCV sequence from 16 subclones; we isolated two
groups of eight subclones (one group each from clones #6 and
#7), because we could not establish clone #2; each subclone was
isolated by treating a CsA-resistant clone (#6 or #7) with 6 lM
CsA (Table 1). Although there were several mutations in the
NS3–NS5B protein-coding regions, common mutations were iso-
leucine (I) to valine (V) at amino acid 1280 (T1280V) and aspartic
acid (D) to glutamic acid (E) at amino acid 2292 (D2292E). At 1280,
original Con1 has threonine (T) and was mutated into (I) in Con1
replicon cells.
Fig. 1. Basic characteristics of the nine cyclosporin A-resistant clones. (A) Flow chart outlining the selection of cyclosporin A-resistant HCV replicon clones. (B) Real-time PCR
was used to determine the copy number of each Cys A-resistant clone. The three clones with the highest HCV genome copy number are highlighted in green (Left). Colony
formation assay of mutant #2, 6 and 7 (Right). (For interpretation of the references to color in this ﬁgure legend, the reader is referred to the web version of this article.)
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To deﬁne the mutations responsible for CsA resistance, we con-
structed various chimeric clones that each contained speciﬁc
mutation that arose from CsA selection (Fig. 2A). We could thereby
evaluate each mutation with regard to its effect on CsA resistance.
We found that mutations in two proteins—NS5A and NS4A—signif-
icantly enhanced the resistance against CsA treatment (Fig. 2B). We
also cultured replicon cells with these mutants in the presence of
CsA (up to 2 lM); we found that cells with a D2292E mutation
could survive, but cells with wild-type NS5A or T1280V mutation
could not (Fig. 3A).
The effect of T1280V mutation on colony formation was further
evaluated (Fig. 3B). Introduction of the T1280V mutation in cis to
the D2292E mutation rescued the colony-formation defect of the
D2292E mutant replicon cells; speciﬁcally, the T1280V–D2292E
double-mutant replicon cells had the same colony-forming ability
as the parental replicon cells.3.3. Evaluation of mutations for CsA resistance in other HCV genotypes
We evaluated whether the mutations that conferred CsA resis-
tance to the HCV Con1 strain (genotype 1b) also conferred CsA
resistance to the RMT (genotype 1a; AB520610) and JFH1(genotype 2a; AB047639) strains (Fig. 4A, B and Table 2) [1].
D2292E conferred CsA resistance to the HCV strains RMT and
JFH1, but T1280V did not (Table 2), as observed with HCV Con1
strain (Fig. 2E). The amino acid sequences surrounding mutations
other than D2292E showed some differences among three geno-
types (1a, 1b, and 2a) (Fig. 4B). D2292E mutants of these three
genotypes showed resistance to CsA (Fig. 2E, Table 2) but the fold
increase of resistance in genotype 1a and 2a was lower than that of
genotype 1b (Tables 2 and 3). Therefore, there might be some
residue(s) other than D2292E to inﬂuence the resistance to CsA.3.4. Efﬁcacy of mutations in NS5A for conferring CsA resistance
Although D2292E clearly conferred CsA resistance to HCV, other
mutations in NS5A may also have had an effect because constructs
with all four of the original NS5A mutations found in clone #6
mutations were more resistant to CsA than were constructs with
only the D2292E mutation (Fig. 2B and E). We constructed HCV-
luciferase replicons, each with one or more of four mutations
(D2292E, D2303H, S2362G, and E2414K). HuH-7 cells were tran-
siently transfected with RNA of each construct; we then treated
the transfected cells with CsA (Table 3). Of the four single mutants,
all but S2362G conferred some CsA resistance to HCV-luciferase
replicons; notably, combinations of mutations had additive effects
Replacement  
or Mutation IC50 
(µM)
Fold 
change 
NS3 NS4A NS5A
Con1_5.1 (GT1b)
- - - 0.18 1.0
Cs6#6 - - 0.21 1.2
- - Cs6#6 2.10 11.7
Cs6#6 - Cs6#6 2.20 12.2
Cs6#6 V1681A Cs6#6 5.40 30.0
Cyclosporin A 
replacement  
or mutations IC50 
(µM)
Fold 
change 
NS3 NS4A NS5A
Con1_5.1 (GT1b)
- - - 0.09 1.0
Cs6#6 - - 0.10 1.1
- - Cs6#6 0.49 5.4
Cs6#6 - Cs6#6 0.50 5.6
Cs6#6 V1681A Cs6#6 1.80 20.0
NIM811 
Replacement  
or mutation IC50 
(µM)
Fold 
change 
NS3 NS4A NS5A
Con1_5.1 (GT1b)
- - - 0.05 1.0
Cs6#6 - - 0.04 0.8
- - Cs6#6 0.43 7.8
Cs6#6 - Cs6#6 0.40 8.0
Cs6#6 V1681A Cs6#6 0.75 13.7
Debio025 
Replacement  
or mutation IC50 
(µM)
Fold 
change 
NS3 NS4B NS5A
Con1_5.1 
(GT1b)
- - - 0.54 1.0 
Cs6#7 - - 0.59 1.1 
- - Cs6#7 2.36 4.4 
Cs6#7 - Cs6#7 2.51 4.6 
Cs6#7 I1797V Cs6#7 2.44 4.5 
T1280V - - 0.57 1.1 
- - D2292E 1.71 3.1 
T1280V - D2292E 1.76 3.3 
Cyclosporin A 
A
B
C
D
E
neo NS3 NS4 NS5A NS5B 
EMCV-IRES 
* 
* 
* * 
Sub-genomic replicon 
Con1_5.1 (GT1b) 
Con1_5.1_CsA_6µM_#6 
Con1_5.1_CsA_6µM_#7 
Con1_5.1_CsA_6µM_#6_NS3 
Con1_5.1_CsA_6µM_#6_NS5A 
Con1_5.1_CsA_6µM_#6_NS3, NS5A 
Con1_5.1_CsA_6µM_#7_NS3 
Con1_5.1_CsA_6µM_#7_NS5A 
Con1_5.1_CsA_6µM_#7_NS3, NS5A 
Con1_5.1_I1280V 
Con1_5.1_D2292E 
Con1_5.1_I1280V, D2292E 
T
Fig. 2. (A) Schematic representations of 12 Con1 replicon-derived constructs. (B–D) Evaluation of Cs6#6 constructs with regard to resistance to CsA or to each of two CsA
derivatives (NIM811 and Debio025). Real-time PCR was used to measure HCV sub-genome copy number in cells, and IC50s were then determined from the copy number
values. For each construct, the fold change represents the ratio of IC50 values from the construct and the parental Con1 replicon (IC50Construct:IC50Parental). (E) Resistance
to CsA of three Cs6#7 derivative constructs that represent the T1280V and D2292E mutations as each single mutation or as a double mutation.
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HCV replicon with all four mutations showed the strongest CsA
resistance.
3.5. Evaluation of CsA-resistant mutants for resistance to cyclophilin
inhibitors
We further evaluated each of the NS5A mutants for their ability
to confer resistance to each of two other cyclophilin inhibitors, N-
methyl-4-isoleucine-cyclosporin (NIM811, Table 4) and Debio-025
(Table 5). Of the four single mutants, D2292E conferred the highest
resistance, and the combination of all four mutations conferred the
overall highest resistance to NIM811 and to Debio-025. When wecompared CsA, NIM811, and Debio-025, the mutation-mediated
increases in IC50 values were lowest with the Debio-025 treatment
(Tables 3–5).
4. Discussion
Here, we investigated two of nine HCV sub-genomic replicon
cell clones (CsA-resistant HCV mutants) isolated following long-
term dual treatment with CsA and G418. Comparing the HCV
sequences of these two clones (#6 and #7), only two of many
mutant sites were shared between the mutant HCV sequences.
Speciﬁcally, both clones #6 and #7 had a D2292E missense muta-
tion in NS5A and a T1280V missense mutation in NS3. D2292E is
AB
CsA (µM) 
0                 1                 2 
none 
T1280V 
D2292E 
T1280V 
+D2292E 
Con1_5.1 
Mutations
Con1_5.1 
none T1280V T1280V 
D2292E 
D2292E Mutations 
Fig. 3. (A) Resistance to CsA of T1280V and D2292E mutants. While under G418
selection, established replicon cells were treated with CsA at the indicated doses.
(B) Standard methods described in Section 2 were used to determine the colony-
forming abilities of T1280V and D2292E mutants.
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and as a single mutation, it conferred CsA resistance to three sep-
arate HCV strains in our hands. In contrast, T1280V in NS3 was not
previously identiﬁed as a CsA-resistance mutant, and in our hands,
it had no impact on CsA resistance as a single mutation (Figs. 2E
and 3A).Table 1
The list of each mutated amino acid sequences in 16 clones throughout wh
The two gray-highlighted lines were selected as the representative sequ
constructs.D2292E was the most signiﬁcant resistance mutation in this
study (Fig. 4C). This mutation is also signiﬁcant in the regulation
of HCV genome replication [29], and close to the CypA binding
region [30] (Supplementary Fig. 1). With several genotypes (1a,
1b, 2a, 3, 4, and 6), D2292E is frequently observed after Debio-
025 selection [28,31]. Other different mutations in NS5A and
NS5B were identiﬁed in other studies of CsA resistance [7]; there-
fore, various mutations could inﬂuence HCV resistance to CsA.
In addition to the D2292E mutation, the T1280V mutation in
NS3 was present in both clones #6 and #7. Despite its presence
in both clones, it did not confer CsA resistance as a single mutant,
nor did it enhance the effects of the NS5A CsA-resistant mutants
(Fig. 2E). Instead, it partially rescued the colony-forming defect
caused by D2292E (Fig. 3B). We used three assays—colony forma-
tion assay without CsA treatment (Fig. 3B), cell survival assay of
established replicon cells with CsA and G418 dual-treatment
(Fig. 3A), and HCV replication inhibition assay without G418 treat-
ment (Fig. 2E and Table 2)—to evaluate the HCV replication compe-
tence of each of these two mutations (D2292E, T1280V). It is
difﬁcult to fully explain all of the results, and comparison of the
two CsA-resistant clones (clone #6 and #7) leaves some questions
unanswered. These clones were similar to each other when consid-
ering survival during CsA and G418 dual-treatment (Fig. 1B), but
they show differences in their resistance in HCV sub-genome rep-
lication assay (Fig. 2B and E). Apparently, each mutation in clone
#7, except for D2292E, had no effect on the results of the HCV
sub-genome replication inhibition assay with CsA. These ﬁndings
might suggest that these mutations were important to G418 resis-
tance, but not to the resistance of HCV to CsA treatment. In con-
trast, each of three other mutations in NS5A (D2303H, S2362G,
and E2414K) that were found in clone #6 were required for the
maximum level of drug resistance conferred by a mutant NS5A
in this study. To our knowledge, D2303H is a novel CsA-resistant
mutation, and as a single mutation, it conferred CsA resistance
comparable to D2292E. D2303H, like D2292E, was located in car-
boxy-terminal of domain II of NS5A, which is reportedly a CypA
binding site [9]. S2362G and E2414K were mutations in domain
III of NS5A, and these mutations may have inﬂuenced the pepti-
dyl-prolyl isomerase enzymatic catalytic activity of CypA [22].
The V1681A mutation in NS4A identiﬁed in clone #6 greatly
enhanced the CsA resistance of a HCV construct that had NS3
and NS5A replaced with Cs6#6 sequences (Fig. 2B–D). Thoughole non-structural region.
ences of CsA_6lM_#6 and #7 and used to generate the derivative
Fig. 4. Amino acid sequences of HCV-RMT-tri (GT1a) and HCV-JFH1 (GT2a) around (A) T1280V and (B) D2292E. (C) Location of the CsA resistant mutations in NS5A. Amino
acid sequences around the positions of four CsA resistant mutations.
Table 2
Evaluation of resistance to CsA of mutants that have single mutations or combinations
of multiple mutations.
Mutations IC50 (lm) Fold change
NS3 NS5A
RMT-tri (RMT, GT1a) – – 0.79 1.0
– D2292E 2.1 2.7
T1280I – 0.96 1.2
T1280I D2292E 2.46 3.1
T1280V – 0.91 1.2
T1280V D2292E 2.54 3.2
JFH1 (JFH1, GT2a) – – 0.49 1.0
– D2292E 1.3 2.7
T1280I – 0.51 1.0
T1280I D2292E 1.38 2.8
T1280V – 0.69 1.4
T1280V D2292E 1.2 2.4
Threonine at site 1280 (RMT-tri or JFH1) were mutated to isoleucine (adaptive
mutation of Con1 replicon) or valine (major mutation of CsA resistant clones).
Aspartic acid at 2292 was mutated to glutamic acid.
Table 3
Evaluation of amino acid mutations in NS5A that conferred CysA resistance.
Mutations in NS5A IC50
(lm)
Fold
change
D2292E D2303H S2362G E2414K
Con1_5.1
(GT1b)
0.11 1.0
s 0.88 7.9
s 0.52 4.7
s 0.12 1.0
s 0.30 2.7
s s s 1.0 9.4
s s 1.8 16.6
s s 0.95 8.5
s s 1.5 13.1
s s s s 2.80 25.7
Table 4
Evaluation of amino acid mutations in NS5A that conferred NIM811 resistance.
Mutations in NS5A IC50
(lm)
Fold
change
D2292E D2303H S2362G E2414K
Con1_5.1
(GT1b)
0.054 1.0
s 0.324 6.0
s 0.184 3.4
s 0.056 1.0
s 0.125 2.3
s s s 0.455 8.4
s s 0.635 11.8
s s 0.403 7.5
s s 0.599 11.1
s s s s 0.923 17.1
Table 5
Evaluation of amino acid mutations in NS5A that conferred Debio-025 resistance.
Mutations in NS5A IC50
(lm)
Fold
change
D2292E D2303H S2362G E2414K
Con1_5.1
(GT1b)
0.024 1.0
s 0.095 4.0
s 0.074 3.1
s 0.028 1.2
s 0.024 1.8
s s s 0.139 5.8
s s 0.198 8.3
s s 0.139 5.8
s s 0.185 7.8
s s s s 0.263 11.0
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mechanism of CsA resistance and its cooperation with other muta-
tions in NS3 and NS5A must be worthwhile because V1681A
greatly enhanced the CsA resistance of some constructs.
In all, we evaluated three cyclophilin inhibitors—CsA, NIM811,
and Debio-025. Among them, Debio-025 showed the strongest
inhibition (IC50 values to any mutants) and was tolerated by
CsA-resistant mutations (IC50 index change values, Fig. 2 andTable 3–5). It was interesting that the resistant mutants differed
so greatly in their tolerance of these three inhibitors because all
three inhibitors have the same mode of action. Garcia-Rivera
et al. concluded that CsA resistance of HCV mutants were solely
derived from dependence of the NS5A proteins on cyclophilins
[28]. Our results might indicate that other factors are important
to CsA resistance, in addition to residual cyclophilin activity.
Drugs that are intended to treat chronic HCV infection and that
target important nonstructural HCV proteins—the serine protease
NS3/4A, the large phosphoprotein NS5A, or the RNA-dependent
RNA polymerase NS5B—have reached the clinical trial stage of drug
development [32–34]. Two oral HCV protease inhibitors were
approved by the FDA, and some of the drugs could achieve a sus-
62 M. Arai et al. / Biochemical and Biophysical Research Communications 448 (2014) 56–62tained virologic response (SVR) [35]. However, to develop treat-
ments that eradicate individual chronic HCV infections, additional
studies on the emergence of drug-resistant HCV mutants and on
the molecular interactions at HCV replication complexes are
necessary.
Our new ﬁndings provided insights into the way by which HCV
acquires resistance to cyclophilin inhibitors, and these insights will
facilitate the development of this type of anti-HCV drug for clinical
use.
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